menu
    • menu
    [{"orgOrder":0,"company":"Sichuan Kelun Pharmaceutical","sponsor":"Levena Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"A166","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Sichuan Kelun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Kelun Pharmaceutical \/ Sichuan Kelun-Biotech Biopharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Sichuan Kelun Pharmaceutical \/ Sichuan Kelun-Biotech Biopharmaceutical"},{"orgOrder":0,"company":"Sichuan Kelun Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Macromolecule-based Therapeutic","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sichuan Kelun Pharmaceutical","amount2":1.4099999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":1.4099999999999999,"dosageForm":"","sponsorNew":"Sichuan Kelun Pharmaceutical \/ Merck & Co.","highestDevelopmentStatusID":"1","companyTruncated":"Sichuan Kelun Pharmaceutical \/ Merck & Co."},{"orgOrder":0,"company":"Sichuan Kelun Pharmaceutical","sponsor":"Levena Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"A166","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Sichuan Kelun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sichuan Kelun Pharmaceutical \/ Levena Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Sichuan Kelun Pharmaceutical \/ Levena Biopharma"},{"orgOrder":0,"company":"Sichuan Kelun Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"SKB571","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sichuan Kelun Pharmaceutical","amount2":0.040000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sichuan Kelun Pharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"14","companyTruncated":"Sichuan Kelun Pharmaceutical \/ Merck & Co"}]

    Find Clinical Drug Pipeline Developments & Deals by Sichuan Kelun Pharmaceutical

    Menu

    Sichuan Kelun Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sichuan Kelun Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sichuan Kelun Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SKB571

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : $37.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Merck & Co. Buys Kelun ADC For $37.5M, Drops Another Asset

                            Details : Merck has taken up its option on SKB571, a bispecific ADC that Kelun sees primarily as a treatment of solid tumors such as lung cancer and gastrointestinal tumors.

                            Brand Name : SKB571

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 20, 2024

                            Lead Product(s) : SKB571

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : $37.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sichuan Kelun Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sichuan Kelun Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : A166

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Levena Biopharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Levena Biopharma, a Sorrento Company, are to Present Pos...

                            Details : A166 is an antibody-drug conjugate (ADC) composed of an anti-HER2 antibody conjugated to Duostatin-5, a novel anti-microtubule Auristatin derivative, via a proprietary stable covalent linker.

                            Brand Name : A166

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 01, 2022

                            Lead Product(s) : A166

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Levena Biopharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sichuan Kelun Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sichuan Kelun Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Macromolecule-based Therapeutic

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Merck & Co

                            Deal Size : $1,407.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            China’s Kelun Pharma Jumps on Licensing New Cancer Drug to Holland’s Merck Sharp & Dohme

                            Details : The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing of upfront cash in exchange for ex-China rights to a “macromolecular tumor project".

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $47.0 million

                            May 16, 2022

                            Lead Product(s) : Macromolecule-based Therapeutic

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Merck & Co

                            Deal Size : $1,407.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sichuan Kelun Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sichuan Kelun Pharmaceutical

                            China arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : A166

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Levena Biopharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Levena Biopharma, A Sorrento Company, Announces Positive Clinical Data for Its Out-Licensed A166 Product Candi...

                            Details : A166, a third-generation antibody-drug conjugate with tubulin inhibitor Duo-5 toxin, cleavable linker and site-specific K-Lock conjugation chemistry, demonstrated antitumor activity with meaningful responses in heavily pretreated subjects with HER2-posit...

                            Brand Name : A166

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 03, 2022

                            Lead Product(s) : A166

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Levena Biopharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth